ClinicalTrials.gg
TerminatedNCT07073820Updated Nov 2, 2026

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

A Phase 2 interventional study of PF-07868489 in Pulmonary Hypertension, sponsored by Pfizer. Terminated at 27 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.
Updated Nov 2, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies in Hypertension, Pulmonary with a site in Germany — 21 open to participants now, 28 under way, 6 of them phase 3. Hypertension, Pulmonary · Germany.

Enrollment
67th of 105
42 · median 86
Started
2025
with 2 others
Phase 2
36 of 150
2 open now
Registered
143rd of 150
by date

Among the 150 studies in Hypertension, Pulmonary with a site in Germany, this one is the 67th largest by enrollment of the 105 interventional ones that give a count, is one of 3 that started in 2025, is one of 36 in phase 2, and was the 143rd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

21 of the 150 studies in Hypertension, Pulmonary with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertension, Pulmonary with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.

This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

03

Conditions studied

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

This study is seeking participants who are:

  • aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study.
  • willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • do not have worsening or hospitalization for worsening PAH during the qualifying study.
  • not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH.
  • do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study.
  • not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem).
  • not currently prescribed or taking medicines called as GLP-1 agonist.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Open Label

    Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

    Drug: PF-07868489

Interventions

  • DrugPF-07868489

    Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to week 111

  2. Number of Participants With Change From Baseline in Laboratory Tests Results

    Time frame: Baseline up to week 111

  3. Number of Participants With Vital Sign Abnormalities

    Time frame: Baseline up to week 111

Secondary outcomes

  1. Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters

    Time frame: Baseline up to week 111

  2. Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration

    Time frame: Baseline up to week 104

  3. Minimum Observed Plasma Trough Concentration (Cmin), as data permits

    Time frame: Baseline up to week 111

  4. Incidence of Anti-Drug Antibody (ADA)

    Time frame: Baseline up to week 111

07

Study locations

27 sites
  • UCSF Health St. Mary's Hospital
    San Francisco, California 94117, United States
  • Heart and Vascular Center
    San Francisco, California 94143, United States
  • UCSF Helen Diller Medical Center at Parnassus Heights
    San Francisco, California 94143, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Pulmonary Hypertension Research Queensland Pty Ltd
    Auchenflower, Queensland 4066, Australia
  • HUB Hôpital Erasme
    Brussels, 1070, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Vseobecna fakultni nemocnice v Praze
    Prague, 12808, Czechia
  • Thoraxklinik-Heidelberg gGmbH
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Bavaria 93053, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH
    Giessen, Hesse 35392, Germany
  • Universitätsmedizin Greifswald
    Greifswald, Mecklenburg-Vorpommern 17475, Germany
  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
    Dresden, Saxony 01307, Germany
  • Kobe University Hospital
    Kobe, Hyōgo 650-0017, Japan
  • St. Marianna University Hospital
    Kawasaki, Kanagawa 216-8511, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama, 701-1192, Japan
  • Gachon University Gil Medical Center
    Incheon, Incheon-gwangyeoksi [incheon] 21565, South Korea
  • Seoul National University Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
  • Samsung Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 06351, South Korea
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hammersmith Hospital
    London, Greater London W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Oct 2026, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2028 → Oct 2026 and completion Aug 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 18, 2025
StartActual
Nov 10, 2025
Primary completionActual
Oct 9, 2026was Aug 2028
CompletionActual
Oct 9, 2026was Aug 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.
changed Nov 2, 2026
Primary completion
Aug 24, 2028→Oct 9, 2026 (actual)
Nov 2, 2026
Study completion
Aug 24, 2028→Oct 9, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Terminated
    Why stopped The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.
    Primary completion Aug 24, 2028→Oct 9, 2026 (now actual)
    Study completion Aug 24, 2028→Oct 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07073820
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 18, 2025
Start date
Nov 10, 2025
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Nov 2, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion